1. Epilepsy: a public health imperative. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO.
  2. Scharfman H. The Neurobiology of Epilepsy. Curr Neurol Neurosci Rep.2007;7(4):48–354
  3. Fisher RS et al. ILAE Official Report. A practical clinical definition of epilepsy. Epilepsia. 2014;55(4):475-482
  4. Berg AT et al., Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia. 2010;51(4):676-685
  5. Fisher RS et al. Epileptic Seizures and Epilepsy: Definitions Proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia. 2005;(46):470-472)
  6. Fisher RS et al. Operational classification of seizure type by the International League Against Epilepsy: Position paper of the ILAE Commission for classification and terminology. Epilepsia. 2017;58 (4):522-530
  7. Schmitz B, et al. Assessing the unmet treatment need in partial-onset epilepsy: looking beyond seizure control. Epilepsia. 2010;51(11):2231–2240
  8. Fisher RS et al. Instruction manual for ILAE 2017 operational classification of seizure type. Epilepsia. 2017;58 (4):531-542).
  9. Chung S, Wang N and Hank N. Comparative retention rates and long-term tolerability of new antiepileptic drugs. Seizure. 2007;16:296‒304.
  10. ILAE/IBE/WHO. Global Campaign Against Epilepsy: Out of the Shadows. 2003.
  11. Epilepsy Alliance Europe. Background information.
  12. WHO Atlas: Epilepsy care in the world, 2005
  13. Fiest KM, et al. Prevalence and incidence of epilepsy: a systematic review and meta-analysis of international studies. Neurol. 2017; 88(3):296-303
  14. Kaiser S, Selai CE and Trimble MR. Long-term follow-up of topiramate and lamotrigine: a perspective on quality of life. Seizure. 2002;11:356–360.
  15. Engel J. Bringing epilepsy out of the shadows. Neurol. 2003;60(9):1412.
  16. Engel J. Approaches to refractory epilepsy. Ann Indian Acad Neurol. 2014;17(Suppl 1):S12–7.
  17. Lhatoo SD and Sander JWAS. Cause specific mortality. Cause-specific mortality in epilepsy. Epilepsia. 200; 46(Suppl. 11):36–39
  18. Dalic L and Cook MJ. Managing drug-resistant epilepsy: challenges and solutions. Neuropsychiatric Dis Treat. 2016;12:2605–2616
  19. Thurman DJ et al, The burden of premature mortality of epilepsy in high-income countries: A systematic review from the Mortality Task Force of the International League Against Epilepsy, Epilepsia. 2017: 58(1):17–26
  20. de Boer H, Mula M and Sander JW. The global burden and stigma of epilepsy. Epilepsy Behav. 2008;12:540–546.
  21. Chen Z, et al. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: A 30-year longitudinal cohort study. JAMA Neurol. 2018;75(3):279–286. 
  22. Kwan P and Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000; 342(5):314-319
  23. Kwan P, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51(6):1069-77.15. 
  24. French J. Refractory epilepsy: clinical overview. Epilepsia. 2007;48(Suppl 1):3–7.
  25. Laxer KD, et al. The consequences of refractory epilepsy and its treatment. Epilepsy Behav. 2014;37:59–70.